Logo
Logo

About Levocetirizine Dihydrochloride API

Product
  • Therapeutic CategoryRespiratory

  • API Technology

    Synthetic

  • Dose Form

    Solution/Tablet

  • Dr Reddy's Development Status

    Available (Commercial)

  • Available Regulatory Filing

    USDMF, Brazil DMF, EUDMF, Korea DMF, CEP Submitted

Mechanism of Action

Levocetirizine, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). The clinical relevance of this finding is unknown.

Indication

XYZAL is a histamine H1-receptor antagonist indicated for:

  • The relief of symptoms associated with perennial allergic rhinitis
  • The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Levocetirizine Dihydrochloride API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Levocetirizine Dihydrochloride API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

FAQs

What is Levocetirizine Dihydrochloride API used for?
  • Treats symptoms of allergic rhinitis and chronic idiopathic urticaria

What is the dosage form and strength currently available for Levocetirizine Dihydrochloride?
  • Available as oral tablets (5 mg) and oral solution (2.5 mg/5 mL)

What are the benefits of Levocetirizine Dihydrochloride API?
  • Relieves allergy symptoms like runny nose, sneezing, and itching Reduces hives and associated itching

How do you store Levocetirizine Dihydrochloride API?
  • Store at 20°C to 25°C (68°F to 77°F), in a cool, dry place, away from moisture and heat

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.